Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Atorvastatin and Clopidogrel Co-Administration After Coronary Stenting in Korean Patients With Stable Angina

  • Kim, Goeng-Bae (Cardiovascular Center, Sun General Hospital) ;
  • Kim, Jeong-Kyung (Cardiovascular Center, Sun General Hospital) ;
  • Park, Sul (Cardiovascular Center, Sun General Hospital) ;
  • Jeong, Jae-Jin (Cardiovascular Center, Sun General Hospital) ;
  • Yoon, Hyung-Sik (Cardiovascular Center, Sun General Hospital) ;
  • Ko, Sang-Hun (Cardiovascular Center, Sun General Hospital) ;
  • Ko, Jae-Ee (Cardiovascular Center, Sun General Hospital) ;
  • Park, Soo-Jin (Cardiovascular Center, Sun General Hospital) ;
  • Nam, Seon-Woo (Department of Neurology, Sun General Hospital) ;
  • Lee, Jae-Hwan (Cardiovascular Center, Chungnam National University Hospital) ;
  • Hyon, Min-Soo (Department of Cardiology, Soonchunhyang University of College of Medicine)
  • Published : 2011.01.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: It was reported that atorvastatin co-administered with clopidogrel for 8 months did not affect the anti-platelet potency of clopidogrel in Korean patients with acute coronary syndrome, but not in patients with stable angina. We investigated whether co-administration of statins with clopidogrel affected the anti-platelet efficacy of clopidogrel in Korean patients with stable angina. Subjects and Methods: This was a randomized, open-label and two-period crossover design study conducted at two centers. Two hundreds thirty three patients with stable angina scheduled for coronary stenting were randomized into two groups. In Group A, 119 patients first received atorvastatin (10 mg) followed by fluvastatin (80 mg) for 12 weeks per treatment. In Group B, 114 patients received the same treatments in reverse order. Results: Baseline adenosine diphosphate (ADP, 10 $\mu$mol/L)-induced platelet aggregation was 54.4${\pm}$9.1% in Group A and 53.8${\pm}$9.0% in Group B (p=0.44), and significant differences were noted after each treatment period (p<0.001). Inhibition of platelet aggregation was similar between Group A and Group B at 24 hours following clopidogrel loading (29.2${\pm}$11.0% vs. 30.4${\pm}$12.7%; p=0.42). The two treatment least square means of 12-week ADP (10 mol/L)-induced platelet aggregation [29.50${\pm}$0.79 {standard error (SE)}% on the atorvastatin treatment group vs. 28.16${\pm}$0.70 (SE)% in the fluvastatin treatment group] in a 2${\times}$2 cross-over study were not significantly different (p=0.204). Conclusion: Statin and clopidogrel co-administration for 12 weeks is not associated with attenuated anti-platelet activity of clopidogrel in Korean patients with stable angina after coronary stenting, in support of the findings of similar studies conducted in Caucasian populations.

Keywords

References

  1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39. https://doi.org/10.1016/S0140-6736(96)09457-3
  2. Chae SC. Antiplatelet agents in high-risk patients with coronary artery disease. Korean Circ J 2004;34:23-7.
  3. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared ticlopidine in combination with as-pirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-9. https://doi.org/10.1161/01.CIR.102.6.624
  4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. https://doi.org/10.1056/NEJMoa010746
  5. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomiz-ed and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
  6. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9. https://doi.org/10.1056/NEJM199604253341702
  7. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71. https://doi.org/10.1161/01.CIR.103.15.1967
  8. Schomig A, Mehilli J, Holle H, et al. Statin treatment following coronary stenting and one-year survival. J Am Coll Cardiol 2002;40:854-61. https://doi.org/10.1016/S0735-1097(02)02053-3
  9. Baek JH, Choe KH, Jun JE, et al. Multicenter clinical trial of atorvastatin in patients with hypercholesterolemia. Korean Circ J 2001;31:434-41.
  10. Yun KH, Park HY, Choi JH, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10 mg versus Atorvastatin 20 mg. Korean Circ J 2007;37:154-60. https://doi.org/10.4070/kcj.2007.37.4.154
  11. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-32. https://doi.org/10.1016/0006-2952(92)90445-O
  12. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-7.
  13. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological ac-tivity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6.
  14. Clarke TA, Wakell LA. The metabolism of clopidogrel is catalyzed by human cytochrome p450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9. https://doi.org/10.1124/dmd.31.1.53
  15. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the abi-lity of clopidogrel to inhibit platelet aggregation: a new drug-drug in-teraction. Circulation 2003;107:32-7. https://doi.org/10.1161/01.CIR.0000047060.60595.CC
  16. Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003;24:1744-9. https://doi.org/10.1016/S0195-668X(03)00442-1
  17. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomiz-ed, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4. https://doi.org/10.1161/01.CIR.0000088780.57432.43
  18. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92:285-8. https://doi.org/10.1016/S0002-9149(03)00626-X
  19. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8. https://doi.org/10.1161/01.CIR.0000124581.18191.15
  20. Serebruany VL, Midei MG, Malinin Al, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-7. https://doi.org/10.1001/archinte.164.18.2051
  21. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clo-pidogrel-CYP3A4 statin interaction in patients with acute coronary syn-drome. Heart 2005;91:23-6. https://doi.org/10.1136/hrt.2004.035014
  22. Geisler T, Zürn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008;29:1635-43. https://doi.org/10.1093/eurheartj/ehn212
  23. Hong SJ, Park JY, Kim KA, et al. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. Circ J 2009;73:1111-8. https://doi.org/10.1253/circj.CJ-08-1120
  24. World Medical Association. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (accessed 2 December 2008).
  25. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. https://doi.org/10.1161/01.CIR.101.2.207
  26. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91. https://doi.org/10.3758/BF03193146
  27. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphism of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-9. https://doi.org/10.1253/circj.72.1165
  28. Lee KH, Lee SW, Lee JW, et al. The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow P2Y21 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J 2009; 39:512-8. https://doi.org/10.4070/kcj.2009.39.12.512
  29. Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005;35:476-81. https://doi.org/10.1111/j.1365-2362.2005.01522.x
  30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
  31. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequi-valence Studies. New York: Marcel Dekker;1999.
  32. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. New York: Marcel Dekker;2003.

Cited by

  1. A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: A magnetic resonance imaging study vol.163, pp.3, 2011, https://doi.org/10.1016/j.ahj.2011.12.007
  2. Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease : Is There any Place for Novel Agents? vol.65, pp.6, 2011, https://doi.org/10.1177/0003319713499609
  3. Thromboelastography evaluation of low response to clopidogrel in patients with acute coronary syndrome vol.12, pp.1, 2011, https://doi.org/10.1016/j.ijge.2017.07.007